Navigation Links
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference
Date:7/17/2008

preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect even
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
2. Craig Johnson Joins Ardea Biosciences Board of Directors
3. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
4. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
5. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
6. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
7. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
8. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) ... in particular, drug/device combinations. The current system received a score of 0 (range -10 ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... today announced the,publication of an independent, peer reviewed, ... immune response measured prior to kidney,transplantation using the ... to identify patients that may be at risk ... in the first three,months following transplantation., The ...
... Naval Academy satellite called MidSTAR-1 have proven successful in ... that can check for harmful chemicals and the other ... These technologies were collaboratively developed between NASAs Goddard Space ... Field, Calif.; and Eclipse Energy Systems Inc. of various ...
... Brinks Hofer Gilson & Lione, one of,the largest ... to announce that Meredith Martin Addy has been named ... practice areas by Law & Politics,magazine., Intellectual property ... However, in fourteen years of practice, Ms. Addy is,among ...
Cached Biology Technology:New Independent Research Study Indicates That Cylex's ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection 2New Independent Research Study Indicates That Cylex's ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection 3NASA MidSTAR-1 successful technologies may be revolutionary 2NASA MidSTAR-1 successful technologies may be revolutionary 3NASA MidSTAR-1 successful technologies may be revolutionary 4Meredith Martin Addy Named One of Top 10 Illinois 'Super Lawyers' for 2008 2
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... Innovation in New Zealand have developed a new chemical approach ... treat Alzheimer,s disease. The team used a ... heparan sulphates, which are known to control the formation of ... Heparan sulphates are found in nearly every cell of the ...
... in one of Western Europe,s largest lakes, Lake Geneva, in ... ocean have shown that these small bits of plastic can ... or other small waterborne organisms, the full extent of their ... The study, which is being extending under a mandate by ...
... 2013 /PRNewswire-iReach/ -- The National Association of Specialty ... joined the association as a Founding Corporate Member. ... the industry including specialty pharmacies, pharmaceuticals companies, health ... "We are honored and excited to ...
Cached Biology News:New chemical approach to treat Alzheimer's 2Microplastic pollution prevalent in lakes too 2Microplastic pollution prevalent in lakes too 3CARE Pharmacies Joins National Association of Specialty Pharmacy (NASP) as a Founding Corporate Member 2
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7 ... are large (3-5 mm in diameter) in ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... Sections are large (3-5mm in diameter) in ...
... Opticon real-time PCR detection system uses a ... (450-495 nm) and a photomultiplier tube for ... is built on an DNA Engine thermal ... feature. This item includes the thermal cycler, ...
... Precision-designed for Optimal Microdissection , ... enable the precise and rapid extraction of ... and cytology samples with Laser Capture Microdissection., ... for Downstream Molecular Analysis , All CapSure ...
Biology Products: